Evidence map›Paper›PMID 34878965›Full record

ArticleCell cycle (Georgetown, Tex.)2022

p53-mediated G1 arrest requires the induction of both p21 and Killin in human colon cancer cells.

Dan Luo, Chune Yu, Jing Yu, Chao Su, Shun Li, Peng Liang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Dan LuoDepartment of Immunology, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China.
Chune YuLaboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jing YuLaboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Chao SuLaboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shun LiDepartment of Immunology, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China.
Peng LiangClover Biopharmaceuticals, Chengdu, Sichuan, China.
Sichuan University · CNChengdu Medical College · CNClover Biopharmaceuticals (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main biological function of the tumor suppressor p53 is to control cell cycle arrest and apoptosis. Among the p53 target genes, p21 has been identified as a key player in p53-mediated G1 arrest, while Killin, via its high DNA binding affinity, has been implicated in S and G2/M arrest. However, whether Killin is involved in G1 arrest remains unclear. This research aimed to explore the role of Killin in p53-mediated G1 arrest. Knockout of

Indexed as

Colonic NeoplasmsApoptosisCell CycleCell Line, TumorCyclin-Dependent Kinase Inhibitor p21DNA DamageG2 Phase Cell Cycle CheckpointsHumansTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p21TP53 protein, humanTumor Suppressor Protein p53G1 arrestKillinp21p53proteasome

Identifiers

PMID34878965
PMCPMC8837242
OpenAlexW4200577324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.